MorphoSys AG (MOR): Rentabilitas operasi

MorphoSys Corporation (MOR) - logo korporat

Geopolitical tensions and sanctions are complicating component logistics, slowing the registration of new drugs for MorphoSys AG. The annual operating margin illustrates these challenges, where -219.10 captures the magnitude of this parameter. However, the acquisition by a Swiss behemoth expands the distribution of myelofibrosis therapy, while stable royalties from patented antibodies for lymphoma treatment ensure the business's financial stability.

MOR - Rentabilitas dodolan operasi MorphoSys ing rentang 04.07.2022 - 10.08.2024

MorphoSys AG - rincian analitis lan metrik utama (MOR)

- rega lan prakiraan konsensus rega:
Analisis dhasar perusahaan:MorphoSys Inc, MOR
Produk merek MorphoSys Corporation

For MorphoSys AG, the operating margin reflects the efficiency of antibody monetization through royalties from global partners, excluding the impact of debt load and taxes. Analyzing the operating margin allows for an assessment of the profit share generated by the core business, where steady growth of this indicator confirms the scalability of the scientific model and the stability of the company's cash flows.

Pesaing MorphoSys AG (MOR)

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|YMAB (Y-mAbs Corp) - Margin operasi|Margin dodolan operasi Aura Biosciences (AURA)|Rentabilitas operasi Candel Therapeutics Inc. (CADL)|Margin dodolan operasi Accuray, Inc. ARAY|Rentabilitas operasi sellaslifesciences.com SLS|Tingkat bathi operasi ACTU|CTOR - Rentabilitas operasi|Rentabilitas kegiatan operasi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Rentabilitas operasi|FATE: Rasio bathi operasi|WHWK (Aadi Bioscience, Inc.) - Margin operasi|TCRX (TScan Therapeutics) - Rasio bathi operasi|Rentabilitas operasi Champions Oncology (CSBR)|Rentabilitas kegiatan operasi XBiotech USA|Rentabilitas operasi CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Rentabilitas dodolan operasi|RADX - Rentabilitas operasi|ARTV - Margin operasi|Adlai Nortye Ltd (ANL) - Rentabilitas operasi|Veru Pharma - Tingkat bathi operasi|Rentabilitas operasi Tempest Therapeutics Corp|Rentabilitas dodolan miturut bathi operasi XLO (Xilio Therapeutics, Inc.)|Margin operasi RENB|MURA (Mural Oncology) - Tingkat bathi operasi|Margin operasi KAPA (Kairos Pharma Ltd)|OKUR: Rentabilitas dodolan miturut bathi operasi|GDTC: Margin dodolan operasi|CRIS - Margin operasi|APLM: Margin operasi|Rentabilitas dodolan operasi tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Margin operasi|Margin operasi Genprex Inc.|Margin operasi CLDI|Margin dodolan operasi Sunshine Biopharma, Inc. SBFM|Margin operasi XBIO (Xenetic Biosciences)|Tingkat bathi operasi SLRX|PPBT - Rentabilitas operasi|AONC (aoncology.com) - Rentabilitas dodolan miturut bathi operasi|BGNE: Margin operasi|Checkpoint Therapeutics Inc (CKPT) - Margin operasi|ELEV (Elevation Oncology Inc.) - Margin operasi|icadmed.com (ICAD) - Rentabilitas kegiatan operasi|Margin operasi IKNA|NTBL (Notable Labs) - Tingkat bathi operasi|Margin operasi VIRX (Viracta Therapeutics)|NAYA: Rentabilitas dodolan miturut bathi operasi|Ascentage Pharma Group International - Margin operasi